BNP Paribas Financial Markets
KNTE

BNP Paribas Financial Markets’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

BNP Paribas Financial Markets’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,275
Closed -$111K – 4779
2022
Q3 		$111K Buy
+9,275
New +$121K ﹤0.01% 3724

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BNP Paribas Financial Markets's KNTE Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 9,275 shares — an estimated $111K sold.

BNP Paribas Financial Markets first reported a position in KNTE in Q3 2022 and held it in 1 quarter. The position peaked at $111K in Q3 2022. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 9,275 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $111K.
  • BNP Paribas Financial Markets first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Kinnate Biopharma Inc. Common Stock position peaked at $111K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.